With the increasing circulation of the Delta variant, it has become critically important for the OB/GYN to discuss COVID-19 vaccination with patients, and, specifically, to address concerns related to pregnancy, lactation, and fertility. This article reviews the most recent guidance from the American College of Obstetricians and Gynecologists, the Society of Maternal-Fetal Medicine, and the American Society for Reproductive Medicine on vaccination in reproductive-age individuals.
In an updated policy statement, the American Society for Reproductive Medicine says transgender status should not prevent a patient from accessing fertility preservation. Further, reproductive services should be offered to all interested transgender or nonbinary individuals, barring other disqualifying factors (based on empirical evidence as opposed to bias or stereotypes).
No decreases in implantation rates and live birth rates were present in a retrospective study from a single fertility center examining outcomes of in vitro fertilization in women with an arcuate uterus.
Investigators have attempted to develop screening tests to measure the term “ovarian reserve.” It is important for clinicians to understand the usefulness and limitations of these screening tests and to be able to interpret the results for themselves and their patients.